News RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.4583 ^USD	+0.07%		+1.89%	-68.61%

May. 06	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	MT
May. 06	RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	May. 06	MT
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K	May. 06	PU
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035	May. 06	PR
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	May. 06	CI
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K	Apr. 24	PU
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	Apr. 24	CI
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights	Apr. 09	AQ
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price	Apr. 03	AQ
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023	Mar. 27	CI
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	Mar. 11	MT
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K	Mar. 05	PU
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs	Mar. 05	PR
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	Mar. 05	CI
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication	Feb. 21	AQ
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	Feb. 20	CI
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication	Feb. 20	PR
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL	Jan. 31	AQ
Redhill Biopharma Closes $8 Million Registered Direct Offering of American Depositary Shares	Jan. 26	MT
RedHill Biopharma Announces $8 Million Registered Direct Offering	Jan. 26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News RedHill Biopharma Ltd.

Equities

RDHL

US7574682024

Summary

Filters